| No | Primary DI | Version or Model | Catalog Number | Device Description | Product Code | Product Code Name | Device Class | Brand Name |
|---|---|---|---|---|---|---|---|---|
| 1 | 00859812006058 | PROSIGNA-010 | PROSIGNA-010 | Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nC Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Dx Analysis System are a nucleic acid hybridization, visualization and image analysis system based upon coded probes designed to detect the messenger RNA transcribed from 58 genes. The test input is purified RNA from FFPE breast tumor specimens which are acquired from surgical resection. The Prosigna assay uses gene-specific probe pairs that hybridize directly to the mRNA transcripts in solution. The nCounter Dx Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of the mRNA transcripts. Prosigna simultaneously measures the expression levels of 50 genes used in the PAM50 classification algorithm (Parker et al., 2009), 8 housekeeping genes used for signal normalization, 6 positive controls, and 8 negative controls in a single hybridization reaction, using nucleic acid probes designed specifically to those genes. The software algorithm produces a Prosigna Score (referred to as ROR Score or Risk of Recurrence Score in the literature (Dowsett et al., 2013)) based on the similarity of the expression profile to each PAM50 molecular subtype, as well as the gross pathological tumor size and a proliferation score computed from a subset of genes. Three risk categories (Low, Intermediate and High) were defined based on a study with over 1007 patient samples associating Prosigna score with long-term outcome. The required components for the Prosigna Assay include the RNA Isolation kit (manufactured by Roche), Prosigna reagents (Reference Sample, CodeSet, Prep Pack, Cartridge(s) and Prep Plate) and the instruments that comprise the nCounter Dx Analysis System; the Prep Station and Digital Analyzer. The test output is a patient specific report which includes a Prosigna Score (0-100) and risk category (low/intermediate/high) where indicated. | NYI | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 2 | Prosigna Breast Cancer Prognostic Gene Signature Assay |
| 2 | 00859812006041 | PROSIGNA-004 | PROSIGNA-004 | Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nC Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Dx Analysis System are a nucleic acid hybridization, visualization and image analysis system based upon coded probes designed to detect the messenger RNA transcribed from 58 genes. The test input is purified RNA from FFPE breast tumor specimens which are acquired from surgical resection. The Prosigna assay uses gene-specific probe pairs that hybridize directly to the mRNA transcripts in solution. The nCounter Dx Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of the mRNA transcripts. Prosigna simultaneously measures the expression levels of 50 genes used in the PAM50 classification algorithm (Parker et al., 2009), 8 housekeeping genes used for signal normalization, 6 positive controls, and 8 negative controls in a single hybridization reaction, using nucleic acid probes designed specifically to those genes. The software algorithm produces a Prosigna Score (referred to as ROR Score or Risk of Recurrence Score in the literature (Dowsett et al., 2013)) based on the similarity of the expression profile to each PAM50 molecular subtype, as well as the gross pathological tumor size and a proliferation score computed from a subset of genes. Three risk categories (Low, Intermediate and High) were defined based on a study with over 1007 patient samples associating Prosigna score with long-term outcome. The required components for the Prosigna Assay include the RNA Isolation kit (manufactured by Roche), Prosigna reagents (Reference Sample, CodeSet, Prep Pack, Cartridge(s) and Prep Plate) and the instruments that comprise the nCounter Dx Analysis System; the Prep Station and Digital Analyzer. The test output is a patient specific report which includes a Prosigna Score (0-100) and risk category (low/intermediate/high) where indicated. | NYI | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 2 | Prosigna Breast Cancer Prognostic Gene Signature Assay |
| 3 | 00859812006034 | PROSIGNA-003 | PROSIGNA-003 | Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nC Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Dx Analysis System are a nucleic acid hybridization, visualization and image analysis system based upon coded probes designed to detect the messenger RNA transcribed from 58 genes. The test input is purified RNA from FFPE breast tumor specimens which are acquired from surgical resection. The Prosigna assay uses gene-specific probe pairs that hybridize directly to the mRNA transcripts in solution. The nCounter Dx Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of the mRNA transcripts. Prosigna simultaneously measures the expression levels of 50 genes used in the PAM50 classification algorithm (Parker et al., 2009), 8 housekeeping genes used for signal normalization, 6 positive controls, and 8 negative controls in a single hybridization reaction, using nucleic acid probes designed specifically to those genes. The software algorithm produces a Prosigna Score (referred to as ROR Score or Risk of Recurrence Score in the literature (Dowsett et al., 2013)) based on the similarity of the expression profile to each PAM50 molecular subtype, as well as the gross pathological tumor size and a proliferation score computed from a subset of genes. Three risk categories (Low, Intermediate and High) were defined based on a study with over 1007 patient samples associating Prosigna score with long-term outcome. The required components for the Prosigna Assay include the RNA Isolation kit (manufactured by Roche), Prosigna reagents (Reference Sample, CodeSet, Prep Pack, Cartridge(s) and Prep Plate) and the instruments that comprise the nCounter Dx Analysis System; the Prep Station and Digital Analyzer. The test output is a patient specific report which includes a Prosigna Score (0-100) and risk category (low/intermediate/high) where indicated. | NYI | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 2 | Prosigna Breast Cancer Prognostic Gene Signature Assay |
| 4 | 00859812006027 | PROSIGNA-002 | PROSIGNA-002 | Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nC Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Dx Analysis System are a nucleic acid hybridization, visualization and image analysis system based upon coded probes designed to detect the messenger RNA transcribed from 58 genes. The test input is purified RNA from FFPE breast tumor specimens which are acquired from surgical resection. The Prosigna assay uses gene-specific probe pairs that hybridize directly to the mRNA transcripts in solution. The nCounter Dx Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of the mRNA transcripts. Prosigna simultaneously measures the expression levels of 50 genes used in the PAM50 classification algorithm (Parker et al., 2009), 8 housekeeping genes used for signal normalization, 6 positive controls, and 8 negative controls in a single hybridization reaction, using nucleic acid probes designed specifically to those genes. The software algorithm produces a Prosigna Score (referred to as ROR Score or Risk of Recurrence Score in the literature (Dowsett et al., 2013)) based on the similarity of the expression profile to each PAM50 molecular subtype, as well as the gross pathological tumor size and a proliferation score computed from a subset of genes. Three risk categories (Low, Intermediate and High) were defined based on a study with over 1007 patient samples associating Prosigna score with long-term outcome. The required components for the Prosigna Assay include the RNA Isolation kit (manufactured by Roche), Prosigna reagents (Reference Sample, CodeSet, Prep Pack, Cartridge(s) and Prep Plate) and the instruments that comprise the nCounter Dx Analysis System; the Prep Station and Digital Analyzer. The test output is a patient specific report which includes a Prosigna Score (0-100) and risk category (low/intermediate/high) where indicated. | NYI | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 2 | Prosigna Breast Cancer Prognostic Gene Signature Assay |
| 5 | 00859812006010 | PROSIGNA-001 | PROSIGNA-001 | Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nC Used together, the Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Dx Analysis System are a nucleic acid hybridization, visualization and image analysis system based upon coded probes designed to detect the messenger RNA transcribed from 58 genes. The test input is purified RNA from FFPE breast tumor specimens which are acquired from surgical resection. The Prosigna assay uses gene-specific probe pairs that hybridize directly to the mRNA transcripts in solution. The nCounter Dx Analysis System delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of the mRNA transcripts. Prosigna simultaneously measures the expression levels of 50 genes used in the PAM50 classification algorithm (Parker et al., 2009), 8 housekeeping genes used for signal normalization, 6 positive controls, and 8 negative controls in a single hybridization reaction, using nucleic acid probes designed specifically to those genes.The software algorithm produces a Prosigna Score (referred to as ROR Score or Risk of Recurrence Score in the literature (Dowsett et al., 2013)) based on the similarity of the expression profile to each PAM50 molecular subtype, as well as the gross pathological tumor size and a proliferation score computed from a subset of genes. Three risk categories (Low, Intermediate and High) were defined based on a study with over 1007 patient samples associating Prosigna score with long-term outcome. The required components for the Prosigna Assay include the RNA Isolation kit (manufactured by Roche), Prosigna reagents (Reference Sample, CodeSet, Prep Pack, Cartridge(s) and Prep Plate) and the instruments that comprise the nCounter Dx Analysis System; the Prep Station and Digital Analyzer. The test output is a patient specific report which includes a Prosigna Score (0-100) and risk category (low/intermediate/high) where indicated. | NYI | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 2 | Prosigna Breast Cancer Prognostic Gene Signature Assay |
| 6 | 00859812006065 | NCT-PREP-STATION-FLEX | NCT-PREP-STATION-FLEX | The Prep Station is a part of the nCounter DX Analysis System, which consists of The Prep Station is a part of the nCounter DX Analysis System, which consists of two instruments, the nCounter Prep Station 5s and the nCounter Digital Analyzer 5s. The Prep Station is the automated fluidic handling component of the nCounter DX Analysis System which processes samples post-hybridization. The samples prepared by the Prep Station are used for data collection on the nCounter Digital Analyzer. Together,the NanoString nCounter DX Analysis System (liquid handling robot and epifluorescence scanner) delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of mRNA transcripts using the following steps: 1) a hybridization of the mRNA to fluorescent Reporter Probes and Capture Probes, 2) purification of the target/probe complexes using nCounter Prep Plates containing reagents necessary for post-hybridization processing and immobilization onto the nCounter Cartridge on the nCounter Prep Station, and 3) analysis of the nCounter Cartridge on the nCounter Digital Analyzer to provide a test result. | NSU | Instrumentation For Clinical Multiplex Test Systems | 2 | nCounter Prep Station 5s |
| No | Primary DI | Version or Model | Catalog Number | Device Description | Brand Name | Organization Name |
|---|---|---|---|---|---|---|
| 1 | 08430793040532 | 724120 | 1. Aptiva Celiac Disease IgA Reagent Cartridge contains reagents to process 250 1. Aptiva Celiac Disease IgA Reagent Cartridge contains reagents to process 250 samples.a. tTG, DGP, and Control paramagnetic particles, preserved. b. Assay Buffer – colored pink, containing protein stabilizers and preservatives.c. PE Tracer IgA – PE labeled anti-human IgA antibody, containing buffer, protein stabilizers and preservative.d. Rehydration Buffer - containing protein stabilizers and preservatives | Aptiva® Celiac Disease IgA Reagent | INOVA DIAGNOSTICS, INC. | |
| 2 | 05700571108703 | G5761A | SureScan Dx Microarray Scanner | SureScan Dx Microarray Scanner | AGILENT TECHNOLOGIES SINGAPORE PTE LTD | |
| 3 | 03610520550984 | 1844095-IVD | 1844095-IVD | CFX96 Dx and CFX96 Deep Well Dx Systems | CFX96 | BIO-RAD LABORATORIES, INC. |
| 4 | 03610520540695 | version 4.3 | 12000964 | BioPlex 2200 Operation Manual version 4.3 Multiple Language CD-ROM | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 5 | 03610520540633 | SW Version 4.3 | 12000958 | BioPlex 2200 System Operation Manual , Software Version 4.3 | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 6 | 03610520505915 | SW Version 4.2 | 6600813-4.2.1 | BioPlex 2200 System Operation Manual , Software Version 4.2 | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 7 | 03610520457818 | 1845097-IVD | 1845097-IVD | CFX96 Dx and CFX96 Deep Well Dx Systems | CFX96 | BIO-RAD LABORATORIES, INC. |
| 8 | 03610520010167 | 660-0818 | 6600818 | BioPlex 2200 Instrument Wash Buffer, 1 X 10 L | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 9 | 03610520010150 | 660-0817 | 6600817 | BioPlex 2200 Instrument Sheath Fluid, 2 X 4L | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 10 | 00875197005561 | 07557272190 | 07557272190 | cobas omni Utility Channel Reagent Kit | ROCHE DIAGNOSTICS GMBH | |
| 11 | 00875197005134 | 07002238190 | 07002238190 | cobas® Buffer Negative Control Kit | ROCHE DIAGNOSTICS GMBH | |
| 12 | 00860006465612 | Azure Cielo 6 Dx | Azure Cielo Dx | AZURE BIOSYSTEMS INC. | ||
| 13 | 00860006465605 | Azure Cielo 3 Dx | Azure Cielo Dx | AZURE BIOSYSTEMS INC. | ||
| 14 | 00859812006065 | NCT-PREP-STATION-FLEX | NCT-PREP-STATION-FLEX | The Prep Station is a part of the nCounter DX Analysis System, which consists of The Prep Station is a part of the nCounter DX Analysis System, which consists of two instruments, the nCounter Prep Station 5s and the nCounter Digital Analyzer 5s. The Prep Station is the automated fluidic handling component of the nCounter DX Analysis System which processes samples post-hybridization. The samples prepared by the Prep Station are used for data collection on the nCounter Digital Analyzer. Together,the NanoString nCounter DX Analysis System (liquid handling robot and epifluorescence scanner) delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of mRNA transcripts using the following steps: 1) a hybridization of the mRNA to fluorescent Reporter Probes and Capture Probes, 2) purification of the target/probe complexes using nCounter Prep Plates containing reagents necessary for post-hybridization processing and immobilization onto the nCounter Cartridge on the nCounter Prep Station, and 3) analysis of the nCounter Cartridge on the nCounter Digital Analyzer to provide a test result. | nCounter Prep Station 5s | NANOSTRING TECHNOLOGIES, INC. |
| 15 | 00859812006003 | NCT-DIGITAL-ANALYZER-FLEX | NCT-DIGITAL-ANALYZER-FLEX | The Digital analyzer is a part of the nCounter DX Analysis System, which consist The Digital analyzer is a part of the nCounter DX Analysis System, which consists of two instruments, the nCounter Prep Station 5s and the nCounter Digital Analyzer 5s. The Digital Analyzer is a multi-channel epifluorescence scanner configured specifically for use with NanoString’s nCounter Test Kit Cartridges.The nCounter Digital Analyzer collects data by taking images of the immobilized fluorescent reporters in the sample cartridge with a CCD camera through a microscope objective lens. Together,the NanoString nCounter DX Analysis System (liquid handling robot and epifluorescence scanner) delivers direct, multiplexed measurements of gene expression through digital readouts of the relative abundance of mRNA transcripts using the following steps: 1) a hybridization of the mRNA to fluorescent Reporter Probes and Capture Probes, 2) purification of the target/probe complexes using nCounter Prep Plates containing reagents necessary for post-hybridization processing and immobilization onto the nCounter Cartridge on the nCounter Prep Station, and 3) analysis of the nCounter Cartridge on the nCounter Digital Analyzer to provide a test result. | nCounter Digital Analyzer 5s | NANOSTRING TECHNOLOGIES, INC. |
| 16 | 00857573006409 | 10-0000-07R | The Verigene® Processor SP is an instrument which integrates sample preparation, The Verigene® Processor SP is an instrument which integrates sample preparation, target amplification, and target hybridization within a single device as part of the Verigene® System, a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid targets of interest for a variety of applications. (Refurbished) | Verigene® Processor SP (Refurbished) | NANOSPHERE, INC. | |
| 17 | 00857573006393 | 10-0000-02R | The Verigene® Reader is the central control of the Verigene® System, a benchtop The Verigene® Reader is the central control of the Verigene® System, a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid targets of interest for a variety of applications. (Refurbished) | Verigene® Reader (Refurbished) | NANOSPHERE, INC. | |
| 18 | 00857573006386 | 10-0000-04 | The Verigene® Processor is an instrument which internalizes all of the functions The Verigene® Processor is an instrument which internalizes all of the functions required to process a Test Cartridge as part of the Verigene® System, a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid targets of interest for a variety of applications. | Verigene® Processor | NANOSPHERE, INC. | |
| 19 | 00857573006010 | 10-0000-07 | The Verigene® Processor SP is an instrument which integrates sample preparation, The Verigene® Processor SP is an instrument which integrates sample preparation, target amplification, and target hybridization within a single device as part of the Verigene® System, a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid targets of interest for a variety of applications. | Verigene® Processor SP | NANOSPHERE, INC. | |
| 20 | 00857573006003 | 10-0000-02 | The Verigene® Reader is the central control of the Verigene® System, a benchtop The Verigene® Reader is the central control of the Verigene® System, a benchtop molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid targets of interest for a variety of applications. | Verigene® Reader | NANOSPHERE, INC. | |
| 21 | 00857167005009 | ePlex System Base | ePlex | GENMARK DIAGNOSTICS, INC. | ||
| 22 | 00856826006050 | 2.1 | 610533 | Affymetrix | AFFYMETRIX, INC. | |
| 23 | 00856826006043 | 00-0146 | 00-0146 | Autoloader w/EBR- GCS3000Dx | Affymetrix | AFFYMETRIX, INC. |
| 24 | 00856826006036 | 00-0336 | 00-0336 | GeneChip Scanner GCS 3000Dx v.2 | Affymetrix | AFFYMETRIX, INC. |
| 25 | 00856826006029 | 00-0335 | 00-0335 | Affymetrix GeneChip Fluidics Station FS450Dx v2 | Affymetrix | AFFYMETRIX, INC. |
| 26 | 00851458005143 | NGDS-ASY-0004 | NGDS-ASY-0004 | NGDS FilmArray Configuration kit (no computer included). | FilmArray® 2.0 Instrument NGDS Configuration | BIOFIRE DEFENSE, LLC |
| 27 | 00851458005136 | NGDS-ASY-0007 | NGDS-ASY-0007 | FilmArray® NGDS Warrior Panel - IVD reagent Biothreat Detection Kit containing 30 tests. | FilmArray® NGDS Warrior Panel | BIOFIRE DEFENSE, LLC |
| 28 | 00851458005129 | NGDS-ASY-0002 | NGDS-ASY-0002U | Refurbished IVD Instrument NGDS Configuration. | FilmArray® 2.0 Instrument NGDS Configuration | BIOFIRE DEFENSE, LLC |
| 29 | 00851458005099 | NGDS-ASY-0006 | NGDS-ASY-0006 | FilmArray® NGDS Warrior Panel - IVD reagent Biothreat Detection Kit containing 30 tests. | NGDS | BIOFIRE DEFENSE, LLC |
| 30 | 00851458005051 | NGDS-ASY-0002 | NGDS-ASY-0002 | IVD Instrument NGDS Configuration. | FilmArray® 2.0 Instrument NGDS Configuration | BIOFIRE DEFENSE, LLC |
| 31 | 00851034007073 | 01 | 63-R0001 | In-vitro multiplex assay used with the Biocode MDx 3000 for the detection of res In-vitro multiplex assay used with the Biocode MDx 3000 for the detection of respiratory pathogens. | BioCode Respiratory Pathogen Panel | APPLIED BIOCODE, INC. |
| 32 | 00850027856124 | Mk12.1 | 5506-CE | Fluxergy Analyzer | FLUXERGY, INC. | |
| 33 | 00850009370150 | 03-3220-01 | 03-3220-01 | CYP2C19 drug metabolyzing enzyme genotyping system | INFINITI® CYP2C19 Amplification Mix | AUTOGENOMICS, INC |
| 34 | 00850009370143 | 03-2220-01 | 03-2220-01 | CYP2C19 drug metabolyzing enzyme genotyping system | INFINITI® CYP2C19 Intellipac® Reagent Module | AUTOGENOMICS, INC |
| 35 | 00850009370136 | 03-1220-01 | 03-1220-01 | CYP2C19 drug metabolyzing enzyme genotyping system | INFINITI® CYP2C19 BioFilmChip® Microarray Magazine | AUTOGENOMICS, INC |
| 36 | 00850009370129 | 01-3050-01 | 01-3050-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A and Facto Genotyping system for the detection of Factor II (Prothrombin) G20210A and Factor V Leiden G1691A mutations | INFINITI® Factor II-V Leiden Amplification Mix | AUTOGENOMICS, INC |
| 37 | 00850009370112 | 01-2050-01 | 01-2050-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A and Facto Genotyping system for the detection of Factor II (Prothrombin) G20210A and Factor V Leiden G1691A mutations | INFINITI® Factor II-V Leiden Intellipac® Reagent Module | AUTOGENOMICS, INC |
| 38 | 00850009370105 | 01-1050-01 | 01-1050-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A and Facto Genotyping system for the detection of Factor II (Prothrombin) G20210A and Factor V Leiden G1691A mutations | INFINITI® Factor II-V Leiden BioFilmChip® Microarray Magazine | AUTOGENOMICS, INC |
| 39 | 00850009370099 | 01-3030-01 | 01-3030-01 | Genotyping systme for the detection of the Factor V Leiden G1691A mutation | INFINITI® Factor V Leiden Amplification Mix | AUTOGENOMICS, INC |
| 40 | 00850009370082 | 01-2030-01 | 01-2030-01 | Genotyping system for the detection of the Factor V Leiden G1691A mutation | INFINITI® Factor V Leiden Intellipac® Reagent Module | AUTOGENOMICS, INC |
| 41 | 00850009370075 | 01-1030-01 | 01-1030-01 | Genotyping system for the detection of the Factor V Leiden G1691A mutation | INFINITI® Factor V Leiden BioFilmChip® Microarray Magazine | AUTOGENOMICS, INC |
| 42 | 00850009370068 | 01-3020-01 | 01-3020-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A mutations. | INFINITI® Factor II Amplification Mix | AUTOGENOMICS, INC |
| 43 | 00850009370051 | 01-2020-01 | 01-2020-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A mutation | INFINITI® Factor II Intellipac® Reagent Module | AUTOGENOMICS, INC |
| 44 | 00850009370044 | 01-1020-01 | 01-1020-01 | Genotyping system for the detection of Factor II (Prothrombin) G20210A mutations. | INFINITI® Factor II BioFilmChip® Microarray Magazine | AUTOGENOMICS, INC |
| 45 | 00850009370037 | 10-0070-99 | 10-0070-99 | Instrumentation For Clinical Multiplex Test Systems | INFINITI® High Throughput System (HTS) INCUBATOR | AUTOGENOMICS, INC |
| 46 | 00850009370020 | 10-0060-99 | 10-0060-99 | Instrumentation For Clinical Multiplex Test Systems | INFINITI® High Throughput System (HTS) PROCESSOR | AUTOGENOMICS, INC |
| 47 | 00850009370013 | 10-0030-99 | 10-0030-99 | Instrumentation For Clinical Multiplex Test Systems | INFINITI® High Throughput System (HTS) ACE ANALYZER | AUTOGENOMICS, INC |
| 48 | 00850009370006 | 10-0020-99 | 10-0020-99 | Instrumentation For Clinical Multiplex Test Systems | INFINITI® PLUS ANALYZER | AUTOGENOMICS, INC |
| 49 | 00847865002820 | 6600000RM | 6600000RM | BPX2200, Analyzer System, Refurbishment | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |
| 50 | 00847865002813 | 6600000 | 6600000 | BioPlex 2200 Instrument | BioPlex 2200 | BIO-RAD LABORATORIES, INC. |